Table 6.
Incidence of bleeding events for warfarin, enoxaparin, dabigatran or rivaroxaban for the prophylaxis of VTE and SPAF
| RR, Dabigatran vs Warfarin (95% CI) [29] | RR, Dabigatran vs Enoxaparin (95% CI) [30] | RR, Rivaroxaban vs Warfarin (95% CI) [31] | RR, Rivaroxaban vs Enoxaparin (95% CI) [32] | Incidence (% n/N) [29-32] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Safety | VTE | SPAF | VTE | SPAF | VTE | SPAF | VTE | SPAF | VTE | SPAF |
| Major bleeding Event | 1.5 (0.81-4.52) | 0.82 (0.65-2.38) | 1.35 (0.46-2.78) | - | 1.33 (0.71-5.69) | 0.68 (0.41-1.28) | 1.14 (0.71-3.52) | - | 1.3 (9/694) | 0.1 (1/901) |
| Minor Bleeding Event | 1.86 (0.64-2.26) | 0.84 (0.91-3.46) | 1.04 (0.82-1.33) | - | 1.41 (0.75-3.48) | 0.44 (0.39-2.27) | 1.12 (0.81-2.35) | - | 15.3 (106/6 94) | 0.2 (2/901) |